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a b s t r a c t
We have previously reported that administration of a CD11d monoclonal antibody (mAb) improves recovery in a
clip-compression model of SCI. In this model the CD11d mAb reduces the inﬁltration of activated leukocytes into
the injured spinal cord (as indicated by reduced intraspinal MPO). However not all anti-inﬂammatory strategies
have reported beneﬁcial results, suggesting that success of the CD11d mAb treatment may depend on the type or
severity of the injury. We therefore tested the CD11d mAb treatment in a rat hemi-contusion model of cervical
SCI. In contrast to its effects in the clip-compression model, the CD11d mAb treatment did not improve forelimb
function nor did it signiﬁcantly reduce MPO levels in the hemi-contused cord. To determine if the disparate results using the CD11d mAb were due to the biomechanical nature of the cord injury (compression SCI versus contusion SCI) or to the spinal level of the injury (12th thoracic level versus cervical) we further evaluated the CD11d
mAb treatment after a T12 contusion SCI. In contrast to the T12 clip compression SCI, the CD11d mAb treatment
did not improve locomotor recovery or signiﬁcantly reduce MPO levels after T12 contusion SCI. Lesion analyses
revealed increased levels of hemorrhage after contusion SCI compared to clip-compression SCI. SCI that is accompanied by increased intraspinal hemorrhage would be predicted to be refractory to the CD11d mAb therapy as
this approach targets leukocyte diapedesis through the intact vasculature. These results suggest that the disparate results of the anti-CD11d treatment in contusion and clip-compression models of SCI are due to the different
pathophysiological mechanisms that dominate these two types of spinal cord injuries.
Crown Copyright © 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Intraspinal inﬂammation is a major component of secondary damage following spinal cord injury (SCI) (Bartholdi and Schwab, 1995;
Blight, 1992; Lee et al., 2000; Popovich et al., 2002; Taoka and
Okajima, 1998). Neutrophils inﬁltrate the injured cord, peaking at
12 h in the rat (Donnelly and Popovich, 2008), releasing cytokines,
and free radicals that further damage the spinal cord (Popovich et al.,
1999; Taoka and Okajima, 1998). Strategies that reduce the early neutrophil and monocyte/macrophage inﬁltration are effective in promoting neuroprotection (Bao et al., 2004a,b; Gorio et al., 2007; Hamada et
al., 1996; Nguyen et al., 2007; Saville et al., 2004; Sroga et al., 2003;
Taoka et al., 1997; Tonai et al., 2001).
Preclinical rodent SCI studies have demonstrated the promising effects of a monoclonal antibody (mAb) 217 L that is directed against
⁎ Corresponding author at: Robarts Research Institute, Schulich School of Medicine,
University of Western Ontario, 100 Perth Drive, London, Ontario N6A 5K8, Canada.
E-mail address: abrown@robarts.ca (A. Brown).

the CD11d subunit of the CD11/CD18 integrin found on the surface of
leukocytes and binds to vascular cell adhesion molecule-1 (VCAM-1,
rat and human) and intercellular adhesion molecule-3 (human only).
Blocking this integrin prevents the migration of leukocytes into the
damaged tissue after injury (Grayson et al., 1999; Schnell et al., 1999b;
Van der Vieren et al., 1995). Anti-CD11d mAb treatment has been
shown to reduce secondary damage by decreasing leukocyte inﬁltration
(Bao et al., 2004a,b; Bao et al., 2005). The anti-CD11d mAb treatment results in improved locomotor and autonomic recovery and reduced neuropathic pain in a clip-compression model of spinal cord injury at the
4th or 12th thoracic (T4 or T12) levels in both rats and mice (Ditor et
al., 2006; Geremia et al., 2012; Gris et al., 2004; Oatway et al., 2005).
These results support the anti-integrin treatment as a potentially viable
therapy for SCI. However, not all anti-inﬂammatory therapies are beneﬁcial, especially when used in different injury models (Stirling et al.,
2009). A recent study using anti-CD11d mAb suggests that differences
in the severity or type of injury may be an important determinant in
the efﬁcacy of the treatment (Hurtado et al., 2012; Weaver et al.,
2012). To investigate this idea, we tested the anti-CD11d treatment in

http://dx.doi.org/10.1016/j.expneurol.2017.06.002
0014-4886/Crown Copyright © 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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two models of blunt, non-penetrating SCI to permit comparisons of
treatment effects after contusion versus clip-compression SCI. One
study, executed at the International Collaboration on Repair Discoveries
in Vancouver, BC tested the mAb in a cervical hemi-contusion model of
rat SCI and the other, conducted at the Robarts Research Institute in London ON, tested the mAb in contusion models of SCI at the 12th (T12)
thoracic spinal segment of rats. Our analyses of locomotor recovery,
intraspinal oxidative damage, inﬂammation and hemorrhage in antiCD11d-treated and control rats provides evidence that the anti-CD11d
strategy is most effective in instances where injury severity is modest,
non-pentrating and frank hemorrhage into the injured spinal cord is
minimal.

Post-operative care after the hemi-contusion SCI consisted of subcutaneous buprenorphine injections (0.02 mg/kg Temgesic®, Reckitt
Benkiser Healthcare Ltd., UK) just prior to and at 1 and 2 days after
the surgery and hydration was supplemented with subcutaneous injections of saline (10 ml) for 3 days post injury. These protocols were abbreviated for the rats studied at 24 h after injury. Temperature was
monitored with a rectal thermometer (TCAT-2LV Temperature Controller, Kopf, Tujunga, CA) during the operation and an incubator was used
to maintain a body temperature of 37 °C prior to and after the surgery
until the animals were fully awake and moving about.

2. Materials and methods

Forty-four Wistar rats (17 male rats for behavior study, 18 female
rats for myeloperoxidase (MPO) assay and 9 female rats for histology
studies; Charles River) weighing 225–250 g were pre-medicated with
diazepam (3.5 mg/kg, intraperitoneally; Sabex International Ltd., Boucherville, Quebec, Canada) and atropine (0.05 mg/kg, subcutaneously;
Sigma Chemical, St. Louis, MO). Anesthesia in the rats was induced
with 4% isoﬂurane and maintained with 1.5% isoﬂurane. A laminectomy
was performed to expose the T12 spinal segment and the animal was
mounted into the Inﬁnite Horizon spinal cord impactor frame (Precision
Systems and Instrumentation, Fairfax, VA). Modiﬁed Allis tissue forceps
mounted in a custom frame were used to stabilize the animal by holding
the dorsal processes on the rostral (T9) and caudal (T11) vertebral segments. After positioning the impactor tip, the Inﬁnite Horizon impactor
was then triggered to deliver a 200 kdyne injury with a 30 s dwell time.
Animals were excluded from the study if the force delivered exceeded
the desired force by 10%. Rats were given 10 ml of saline s.c., 5 mg/kg
of Baytril s.c. (Bayer) and buprenophine (0.01 mg/kg s.c.) twice daily
for three days following surgery. The experiments were completed at
24 h, or 8 weeks after the contusion injuries. In the chronic studies, urinary bladders were manually emptied twice daily until bladder function
was regained.

All animal procedures using the cervical hemi-contusion model of
SCI were performed in accordance with the guidelines of the Canadian
Council for Animal Care and approved by the University of British Columbia Animal Care Committee. All animal procedures using the thoracic contusion model and clip-compression model of SCI were conducted
in accordance with Western University Animal Care Committee Guidelines, adhering to the Canadian Guide to the Care and Use of Experimental Animals. All surgeries, behavioral testing and data analysis were
performed by experimenters blinded to the treatment group of the animals. Animals were housed individually in standard cages with food
and water ad libitum and on a 12 h light and dark cycle (See Table 1).
2.1. Cervical hemi-contusion injury
Thirty-three male Sprague-Dawley rats (Charles River Breeding Laboratories) weighing between 300 g to 350 g were used in this study.
Hemi-contusion SCI at the 5th cervical spinal segment (C5) was induced
using the Inﬁnite Horizon (IH) Spinal Cord Impactor as described previously (Lee et al., 2012). Brieﬂy, the rats were anesthetized with 4%
isoﬂurane and placed in a stereotaxic frame in a prone position (maintenance 1.5–2.5% isoﬂurane). A left C5 hemi-laminectomy was performed and the spinal column was stabilized with a custom-made
clamp designed to wedge under the cervical transverse processes of
C4 to C6 (Choo et al., 2009). The clamp was then positioned in a
frame, which was tilted at a 22.5 degree angle off the horizontal plane.
Following positioning of the impactor tip, the IH impactor was then triggered to deliver a set force of 150 kdyne. Animals were excluded from
further study if the measured peak force exceeded 165 kdyne. Animals
were euthanized at 24 h, or 6 weeks after the SCI.

2.2. T12 contusion injury

2.3. Clip-compression injury
Twenty-eight female Wistar rats (Charles River) weighing 200–
250 g were premedicated and anesthetized as described above for contusion injury. The T12 spinal cord segment was exposed by dorsal
laminectomy and injured by a 60 s, 35-g clip-compression, as described
previously (Oatway et al., 2005). After clip-compression SCI, the rats received the same care as those after contusion SCI described above. Spinal cords of these rats were examined at 24 h after SCI.

Table 1
Summary of experimental groups.
Injury

Treatment group

Duration

Assessment

Cervical
Hemi-contusion
(ICORD, UBC)

Anti-CD11d: n = 12, male
1B7: n = 11, male

6 weeks

Anti-CD11d: n = 12, male
1B7: n = 11, male
Anti-CD11d: n = 5, male
1B7: n = 5, male
Anti-CD11d: n = 8, male
1B7: n = 9 males
Anti-CD11d: n = 9, female
1B7: n = 9, female
n = 4, female
n = 5, female

6 weeks

Behavioral: Montoya staircase
Horizontal ladder test
Cylinder rearing test
Histology: sparing (eriochrome Cyanine)

24 h

MPO assay

8 weeks

Behavioral: locomotor testing
(BBB)
MPO assay

T12 contusion
(RRI, Western Univ)

T12 clip compression
(RRI, Western Univ)

Anti-CD11d: n = 9, female
1B7: n = 9, female
n = 4, female
n = 6 female

24 h
24 h
24 h
24 h
24 h
24 h

Gross anatomy
Histology: H&E
Lesion size and hemorrhage analysis
MPO assay
Gross anatomy
Histology: H&E
Lesion size and hemorrhage analysis
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2.4. Antibody treatment
Following unilateral cervical contusion SCI at C5 the animals were
randomized to the following treatment groups with each group comprising ﬁve animals. Rats to have a 24 h survival time were given one
treatment with the anti-CD11d mAb (217 L; 1.0 mg/kg i.v. by tail vein
injection) at 2 h after injury. Rats having a 6–8 week survival time
were given three treatments with the anti-CD11d mAb (1.0 mg/kg,
i.v.) at 2, 24 and 48 h after the injury. Control rats were given an
isotype-matched mAb against dinitrophenol (1B7, 1.0 mg/kg, i.v.). The
rats with thoracic contusion or clip-compression SCI were administered
the mAb following the same protocol. The dose employed in all the current studies was chosen as it was optimized in previous studies of SCI in
rats (Gris et al., 2004; Saville et al., 2004). The CD11d and 1B7 mAb were
generously provided by Eli Lilly & Company (Indianapolis, IN). The speciﬁc number of rats per treatment group in different experiments is stated in Results.
2.5. Behavioral and histological assessments cervical hemi-contusion model
After one week of acclimatization, all rats were individually trained
for 15 days prior to SCI for the horizontal ladder test, cylinder rearing
test, and modiﬁed Montoya staircase. Behavioral recovery was assessed
biweekly until week 6 post-injury.
2.5.1. Montoya staircase test
On ﬁve consecutive days, animals were acclimatized to the staircase
apparatus by placing the apparatus in their home cages with the lid
open so animals could voluntarily enter the narrow corridor with a removable baited double staircase. Food pellets were placed on the staircase and presented bilaterally at 7 graded ‘stages’ (stairs) at varying
depths with increasing reaching difﬁculty (Montoya et al., 1991). Before
testing commenced, the animals were food-restricted for a total 20 h.
On testing days, rats were tested in the staircase box for a period of
15 min each and the number of successfully grasped food pellets and
eaten using each forepaw was counted and recorded; each well was
baited with four food pellets. Because animals are able to use their
tongue to retrieve pellets from the top two steps of the staircase,
reaching scores considered only the bottom ﬁve steps, from which forelimb use was necessary for successful retrieval. Additionally, the maximum distance reached (well #1–7) was determined.
2.5.2. Cylinder rearing test
Animals were individually placed in a topless clear Plexiglas cylinder
measuring 20 cm in diameter and 30 cm in height until 20 incidences of
rearing-explorations were recorded with a HD camcorder (Sony HDRSR12). To determine forelimb usage, independent use of the left, right
and the simultaneous use of both forepaws were assessed for the initial
contact of the cylinder wall and all lateral movements along the wall
during each individual rear. Percent ipsilateral usage was calculated by
adding the number of ipsilateral forelimb placements and the number
of simultaneous forelimb placements divided by the total number of
forelimb placements [percent ipsilateral usage = (ipsilateral forelimb
placements + simultaneous forelimb placements) / total forelimb
placements) × 100].
2.5.3. Horizontal ladder test
Animals were acclimatized for a total of 5 days to run across an elevated horizontal ladder with a length of 70 cm and a width of 15 cm
with irregularly spaced rungs. After acclimatization, baseline performance was assessed with ﬁve horizontal ladder crosses per rat. Performance was captured using a high deﬁnition (HD) camcorder (Sony
HDR-SR12) as the rats traversed across the ladder. The footages were
later replayed in slow motion to analyze the number of forelimb steps
and forelimb errors (slips and falls). The percent ipsilateral forelimb
error was then calculated as number of slips and falls divided by total
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number of steps taken by that paw [percent ipsilateral forelimb error
= (number of error / total number of steps) × 100].
2.5.4. Histological examination
Six weeks after injury, animals were euthanized with an overdose of
sodium pentobarbital as described above and transcardially perfused
with 150 mL 1× PBS followed by 300 ml of 4% paraformaldehyde (PF)
in 0.1 M phosphate buffer. A 5 mm segment of the cervical spinal cord
centered on the injury site was removed, post-ﬁxed for 24 h in 4% PF
and then cryoprotected in 12, 20 and 28% sucrose. The spinal cord segments were frozen on dry ice and stored at −80 °C until further use. A
5 mm block of spinal cord was cut into 10 serial sets of 20 μm thick sections (collecting every other section) using a cryostat and mounted on
glass slides. To quantify tissue sparing, sections were stained with
Eriochrome Cyanine.
Sections were stained with Eriochrome Cyanine (EC) as described by
(Rabchevsky et al., 2001) and counter-stained with Neutral Red. Images
were then captured using a Leica DM5000B microscope with a 2.5× objective. The area of spared white and gray matter were manually traced
and quantiﬁed using Sigma Scan Pro version 5.0.0 (Systat Software Inc.).
White matter was considered spared if the deep blue EC stain on the
myelin was dense and contained proﬁles resembling myelin rings;
spared gray matter was deﬁned as areas in which light EC staining
could be discerned, and the parenchyma was relatively free of macrophages and cavitation. The lesion epicenter was deﬁned as the crosssection with the smallest amount of white matter sparing. Tissue sparing was assessed at 400 μm intervals centered on the lesion epicenter.
2.6. Myeloperoxidase activity assay
The neutrophil and, to a lesser extent, macrophage presence in the
injured cord was measured using a myeloperoxidase (MPO) activity
assay (Bao et al., 2004b). At 24 h post- injury, hemi-contused rats
were euthanized with an overdose of sodium pentobarbital
(107 mg/kg, Bimeda-MTC Animal Health Inc., Cambridge, Ontario, Canada) and T12 contusion and clip-compression SCI rats were euthanized
with a ketamine (100 mg/ml) and xylazine (20 mg/ml) mix (2:1;
0.1 ml/100 g, i.p.). After an intracardiac injection of heparin (0.5 ml),
the rats were perfused transcardially with 250 ml cold 0.9% NaCl. In
the hemi-contused rats, a 1-cm segment of the injured cervical spinal
cord centered on the C5 lesion was removed and divided longitudinally
in half along the central line. The injured side and the contralateral side
were collected separately in the cold vials, frozen immediately in dry
ice, and stored at –80 °C. In T12 contusion and clip compression rats, a
1-cm segment of spinal cord centered on the thoracic lesion site was removed and immediately homogenized. The samples were homogenized
on ice with 5 volumes (w/v) of 50 mm potassium phosphate buffer
(lysis buffer) and 5 volumes (w/v) of 0.5% hexadecyltrimethylammonium
bromide. The inclusion of hexadecyltrimethylammonium bromide was
used to extract MPO from the leukocyte granules. Following centrifugation at 10,000 ×g for 20 min, MPO activity in the supernatant ﬂuid was
determined with 0.3 ml potassium phosphate buffer solution containing
1.23 mg/ml δ-dianisidine dihydorchloride and 0.05% hydrogen peroxide.
The reaction was started by adding 0.1 ml of sample and was stopped
5 min later by adding 0.1 ml 0.1% sodium azide. Absorbance was measured at 460 nm, MPO activity was calculated using a standard curve prepared with puriﬁed MPO and expressed as units/mg protein.
2.7. Locomotor testing in thoracic contusion model
The locomotor recovery of 17 cord-injured rats was assessed using
the 21 point Basso, Beattie and Bresnahan (BBB) open ﬁeld locomoter
scale (Basso et al., 1995). Male rats were used for behavior testing, in
case there was an effect of the female estrus cycle. The animals were
assessed by two or three observers. Individual scores for each hindlimb were averaged for each animal. Locomotor testing was conducted
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on day 3 post-injury and subsequently twice per week for the duration
of the study.

the anti-CD11d mAb group retrieved 2.75 ± 1.1 pellets out of 20,
whereas the 1B7 controls retrieved and consumed 6.1 ± 1.7 pellets.
The maximum distance reached did not differ between the two groups.

2.8. Examination of the cervical and thoracic lesions at 24 h after injury
Rats without mAb treatment were anesthetized (as above) at 24 h
after T12 contusion or compression SCI and perfused with cold 0.9%
NaCl. The injury site was exposed by dissection and examined in situ
to view the extent of hemorrhage apparent on the cord surface. The lesion sites were photographed. In addition, the injury at 24 h after cervical hemi-contusion or T12 thoracic contusion or compression was
examined for characteristics of the lesion, including the amount of hemorrhage within the cord. Rats with these injuries were anesthetized and
perfused with ﬁxative as described above and 5 mm samples centered
on the respective lesions were embedded in OCT (Tissue Tek, Sakura
Finetek U.S.A. Inc., Torrance, CA), sectioned in the longitudinal plane at
16 μm and stained with hematoxylin and eosin. The slides were viewed
using an Olympus microscope (BX50, Olympus America Inc., Center Valley, PA) and photomicrographs were acquired using a digital camera
(Retiga, Quantitative Imaging Corporation, Burnaby, BC, Canada) and
Image Pro software version 5.1 (Media Cybernetics, Silver Spring,
MD). Images of the longitudinal sections were viewed beginning with
the dorsal surface of the cords and were captured when the section of
cord was complete from side to side. Volumes of the lesions and of
blood within the lesion were determined using the Image Pro quantitative software. First, the area of the lesion was determined for each of the
serial sections, and then, knowing the thickness of the sections, mean
volumes of all adjacent sections were summed to provide an estimate
of the total volume of the lesion and blood.
2.9. Statistical analyses
Group data are expressed as mean ± SEM. Outcomes were only
compared between animals of the same gender. Statistical analysis
was performed using one-way or two-way repeated measures Analysis
of Variance (ANOVA). Upon ﬁnding signiﬁcant group variance differences in one-way ANOVA analysis, differences were tested by a HolmSidak's multiple comparison test post-hoc analysis. When only two
groups were compared a Student's t-test was used. Statistical signiﬁcance was set at P ≤ 0.05.
3. Results
3.1. Effect of CD11d mAb on neurological recovery after C5 hemi-contusion
SCI
We previously demonstrated that intravenous delivery of a mAb directed against the CD11d integrin improves locomotor and autonomic
recovery and reduces neuropathic pain in a clip-compression model of
SCI at the 4th or 12th thoracic (T4 or T12) levels in both rats and mice
(Geremia et al., 2012; Gris et al., 2004; Oatway et al., 2005). To test
this therapeutic strategy in a second model of SCI and in an independent
laboratory, we evaluated the anti-CD11d treatment in a rat cervical (C5)
hemi-contusion model (Lee et al., 2012). After hemi-contusion injury
rats were administered either the anti-CD11d mAb 217 L or the isotype
matched control mAb, 1B7 (1.0 mg/kg, i.v. by tail vein injection) at 2, 24
and 48 h after the injury. Behavioral analyses (n = 12 for CD11d treated
rats and n = 11 for 1B7-treated controls) were carried out over a 6 week
survival time.
3.1.1. Montoya's staircase test
The number of pellets retrieved by the forepaw ipsilateral to the injury was video recorded (Fig. 1A). After hemi-contusion SCI, all animals
demonstrated a marked decrease in the number of food pellets retrieved and eaten; there was no signiﬁcant difference between antiCD11d mAb-treated animals and 1B7 controls. At 6 weeks after injury,

3.1.2. Cylinder rearing test
Prior to SCI, paw usage was similar between both groups (Fig. 1B) in
terms of calculated percent paw placements using the cylinder-rearing
test. No signiﬁcant differences were observed between the anti-CD11d
mAb group and 1B7 controls at either 2, 4 or 6 weeks after C5 hemi-contusion. At the end of the experiment (6 weeks post-injury), ipsilateral
usage of anti-CD11d mAb treated animals was 13.6 ± 5.6% compared
to 8.5 ± 3.0% in the 1B7 controls.
3.1.3. Horizontal ladder
Using the horizontal ladder test (Fig. 1C,D), we analyzed foot placement accuracy (percentage of errors). Cervical hemi-contusive SCI led
to increases in errors (slips + falls) for both groups at weeks 2–6 compared to pre-injury performance. No differences were observed between the anti-CD11d mAb and 1B7 control animals at any given time
point. Six weeks after injury, the percent error in the anti-CD11d mAb
group was 33.8 ± 4.1% and the 1B7 control group was 27.0 ± 3.9%.
3.2. Effect of the CD11d mAb on tissue sparing after C5 hemi-contusion SCI
Rats that underwent C5 hemi-contusion SCI were euthanized for histology upon completion of 6 weeks of behavioral testing. The extent of
gray and white matter sparing was measured in EC-stained serial
cross sections 400 μm apart (n = 12 for CD11d treated rats and n =
11 for 1B7-treated controls). Extensive white and gray matter damage
occurred in the cervical spinal cords of all rats after hemi-contusion
SCI (Fig. 2). Six weeks after injury, the gross tissue damage extended
from the lesion epicenter by ~ 2800 μm both rostrally and caudally.
There were no differences between the groups in area of spared white
matter or in area of spared gray matter.
3.3. Effect of CD11d mAb on MPO levels in the spinal cord after C5 hemicontusion SCI
MPO activity in cord homogenates sampled 24 h after SCI is proportional to the presence of neutrophils and, to a lesser extent, phagocytic
macrophages and in our previous studies, anti-CD11d treatment always
reduced this activity signiﬁcantly by approximately 30–40% (Bao et al.,
2004b; Geremia et al., 2012). Spinal cord samples ipsilateral and contralateral to the lesion were taken 24 h after SCI and studied for MPO activity as a marker for neutrophil accumulation/activation (n = 5 per
group). MPO enzymatic activity was increased at 24 h within the injured
ipsilateral spinal cord compared to the uninjured contralateral side
(Fig. 3). Anti-CD11d mAb treatment did not reduce MPO activity at
24 h in the injured ipsilateral or uninjured contralateral spinal cord
compared to 1B7 control values (Fig. 3).
3.4. Effect of the anti-CD11d mAb treatment on locomotor recovery after a
T12 contusion SCI
The study of cervical hemi-contusion demonstrated that the CD11d
mAb did not inﬂuence intra-parenchymal MPO activity, tissue sparing,
or behavioral recovery – all outcome measures that signiﬁcantly improved in our studies of thoracic clip-compression SCI (Bao et al.,
2004a,b; Bao et al., 2005; Gris et al., 2004; Oatway et al., 2005). We
questioned whether the anti-CD11d treatment might be efﬁcacious in
a model of contusion SCI more closely related to our own previous
clip-compression studies. Therefore, we set out to produce a contusion
injury similar to that caused by 35 g clip-compression (duration 60 s)
at the lower thoracic spinal segments. We designed a study of contusion
SCI at the T12 spinal segment, replicating the location of our published
T12 clip-compression studies (Gris et al., 2004; Oatway et al., 2005).
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Fig. 1. Anti-CD11d treatment does not improve behavioral recovery in after a C5 hemi-contusion SCI. (A) Effect of the anti-integrin treatment on Montoya staircase reaching performance.
The average number of pellets reached and eaten at baseline and 2, 4, 6 and 8 weeks post-SCI was recorded. Recovery of skilled limb use, indicated by the number of pellets successfully
retrieved and eaten, was not affected by the anti-CD11d treatment. (B) Effect of the anti-integrin treatment on use of the fore limb ipsilateral to the hemi-contusion SCI. No differences in
the use of the affected forelimb were detected between mAb-treated and control rats. (C, D) Effect of the anti-CD11d mAb on ipsilateral forelimb placement during horizontal ladder
crossing. The average number of steps (C) and the percentage of errors (D, slips and falls) in 1B7 controls and anti-CD11d mAb-treated rats at baseline and post-injury weeks 2, 4 and
6 are indicated. No differences were observed between both groups (n = 12/anti-CD11d; n = 11/1B7) at any time point after injury.

Delivering a contusion injury of 200 kdyne with a dwell time of 30 s
generated BBB scores quite similar to those after 35 g clip-compression
for the ﬁrst 2 weeks after the injury (Fig. 4). At 1 week and 2 weeks after
contusion injury the mean scores were approximately 3 and 5 and we
reported mean scores of approximately 2 and 6 at these times after
clip-compression injury (Oatway et al., 2005). Anti-CD11d treatment
did not improve the BBB scores in the T12 contusion SCI model
(Fig. 4). At 4 weeks after contusion injury, rats treated with CD11d
mAb (n = 8) had average BBB scores of 5.7 ± 0.5 and rats treated
with the control 1B7 mAb had almost identical BBB scores of 5.7 ± 0.6
(n = 9). We continued to test these rats for 8 weeks after injury
and mean BBB scores in the two groups never diverged (two-way
repeated measures ANOVA: time P b 0.0001, treatment P = 0.6157,
time/treatment interaction P = 0.539).
3.5. Anti-CD11d treatment reduces intraspinal MPO activity after T12 clipcompression but not after T12 contusion SCI
The proposed mechanism of anti-CD11d action is to reduce activated
neutrophil and macrophage inﬁltration of the injured spinal cord
(Mabon et al., 2000; Saville et al., 2004). We considered the possibility
that the contusion injury may produce a smaller inﬂammatory response
than clip-compression injury, limiting the target for the CD11d mAb
treatment. We compared MPO activity in homogenates of the T12 lesion
and adjacent area at 24 h after 35 g clip-compression injury or 200
kdyne (30 s dwell) contusion injury (Fig. 5). Signiﬁcant differences
were detected between the anti-CD11d and 1B7 treatment groups
after the SCI (one-way ANOVA: P = 0.0216). After clip-compression at
T12, MPO activity was 29% lower in the anti-CD11d group than in the
control 1B7 group (n = 9, Holm-Sidak's multiple comparison test, P =
0.0424). In contrast, treatment with the CD11d mAb after contusion
SCI did not reduce MPO activity signiﬁcantly in the treated group in
comparison to the 1B7 control group (n = 9, Holm-Sidak's multiple

comparison test, P = 0.1830). Although the mean MPO activity in the
1B7 control group after T12 contusion injury was lower than the
mean MPO activity in the 1B7 control group after T12 clip injury, they
were not signiﬁcantly different from one another (Holm-Sidak's multiple comparison test, P = 0.2067).

3.6. Contusion SCI causes more hemorrhage than clip-compression SCI
The spinal cords of rats were compared at 24 h after T12 injury by
35 g clip-compression (n = 4) or a 200 kdyne contusion with a 30 s
dwell time (n = 4). When viewed in situ, both resulted in signiﬁcant
hemorrhage on the cord surface. The clip-compression injury produced
a hematoma that was conﬁned to a ~ 2 mm wide line at the site of injury
that approximated the width of the aneurysm clip (Fig. 6, top row). The
contusion injury produced a hematoma much wider than after clipcompression that extended 4 mm or more in the rostral and caudal directions from the centre of the injury (Fig. 6, bottom row).
A histological study of the T12 thoracic lesions of rats 24 h after injury by contusion (n = 5) and by clip-compression (n = 6) was undertaken to examine this apparently greater hemorrhage after contusion than
clip-compression SCI. Sections stained with hematoxylin and eosin revealed lesions with pallor, necrosis and areas of cavitation (Fig. 7A).
Upon inspection, the lesions after contusion appeared to be more extensive and to contain greater amounts of hemorrhage within the cord in
contrast to the lesions after clip-compression that appeared smaller
and less hemorrhagic. We compared these photomicrographs to those
of the C5 hemi-contusion lesion in sections stained by hematoxylin
and eosin. These lesions were conﬁned to half the cervical cord, and accordingly were smaller than those we produced in the thoracic cord.
They too contained areas of pallor and necrosis. The outstanding observation from these cervical sections was the extensive hemorrhage
found at the lesion sites (Fig. 7A).
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Fig. 3. Effect of the anti-CD11d treatment on MPO activity in the lesion epicenter in the C5
hemi-contusion model. Average MPO activity as measured in the ipsilateral anti-CD11d
and 1B7-treated control injured spinal cords, 24 h post-injury. The mean levels of MPO
activity were increased in the ipsilateral spinal cord compared to the contralateral side.
No signiﬁcant differences were observed between 1B7 controls and anti-CD11d mAbtreated animals (n = 5/anti-CD11d; n = 5/1B7).

The volumes of lesion and of hemorrhage within the thoracic lesions
were measured by a colour-threshold detecting function of the Image
Pro software. The volume of lesion was ﬁrst calculated as described in
methods, and then the volume of hemorrhage was calculated. The
mean lesion volume after contusion injury was larger but only tended
to be different from the mean lesion volume after clip-compression injury (Fig. 7B, 1-tailed Student's t-test P = 0.06), whereas the volume of
hemorrhage in the sections after contusion injury were signiﬁcantly
greater than after compression injury (Fig. 7C, Student's t-test 2-tailed
P = 0.01).
4. Discussion
Acute intravenous delivery of the CD11d mAb improves locomotor
recovery and reduces pain in rats after a clip-compression SCI. We initially set out to determine whether this therapy would also promote improved functional recovery following C5 hemi-contusion SCI in a
laboratory independent to that where much of the promising work on
CD11d mAb had previously occurred. Using an array of behavioral
tests, no signiﬁcant differences were found between treated and control
groups in the cervical SCI model. Since we had also previously shown
that the CD11d mAb increases white matter sparing (Gris et al., 2004;
Oatway et al., 2005) in the rat clip-compressed spinal cord, we also
assayed white matter and gray matter sparing in the C5 hemi-contused
rat. Again, we found no signiﬁcant difference between treated and control groups on these measures. To evaluate whether the absence of a

Fig. 2. Anti-CD11d treatment does not increase white or gray matter sparing after a C5
hemi-contusion SCI. (A) Photomicrographs of eriochrome cyanine-stained coronal
sections at the injury epicenter of 1B7 control (top) and CD11d mAb-treated (bottom)
rats after C5 hemi-contusion. Bar = 1 mm. The average areas of spared white (B) and
gray (C) matter measured in EC-stained serial sections from 3.6 mm rostral to 3.6 mm
caudal of the center of the injury site are not signiﬁcantly different between 1B7
controls and Cd11d mAb-treated rats (n = 12/anti-CD11d; n = 11/1B7).

Fig. 4. The effect of the CD11d mAb treatment on locomotor recovery following a T12
contusion injury. The CD11d mAb treatment did not improve locomotor recovery after
T12 contusion SCI. There was no difference in BBB scores in the anti-CD11d treated
group (black circles) when compared to 1B7 control treated group (open circles) over
the period of 56 days (n = 8/anti-CD11d; n = 9/1B7).
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Fig. 5. The Anti-CD11d treatment reduces intraspinal myeloperoxidase activity after T12
clip (35 g) compression SCI but not after T12 contusion SCI. MPO activity was measured
24 h post-injury. Treatment with the CD11d mAb signiﬁcantly reduced the amount of
MPO in the T12 clip-compression SCI when compared to isotype control (n = 9/group;)
but not in the T12 contusion SCI (n = 9/group).

treatment effect in the C5 hemi-contusion model might apply to contusion SCI in general, we evaluated the CD11d mAb treatment in a T12
contusion injury. As in the case of the C5 hemi-contusion, the antiCD11d therapy failed to improve locomotor recovery in the cordcontused rats.
To investigate why the CD11d mAb improves recovery in T12 clipcompressed rats but not in T12 contused rats, we evaluated MPO levels
in treated and untreated rats after both types of SCI at 24 h post-injury.
In keeping with our previous reports, the CD11d mAb reduced MPO
levels after T12 clip-compression SCI, however, the treatment did not
reduce MPO levels after T12 contusion SCI. Upon examination of the
gross in situ spinal cords, we observed a striking difference in the
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surface appearance of the cords between the compression and contusion injury groups: the clip-compression injury produced a small hematoma across the cord corresponding to the placement of the clip,
whereas the contusion injury produced a large hemorrhage that appeared to spread in the rostral-caudal axis from the point of impact.
We therefore hypothesized that neutrophils were entering the cord
through different mechanisms in the two different injury models:
CD11d-dependent diapedesis in the case of compression, and
intraparenchymal hemorrhage in the case of contusion. Histological investigation and quantiﬁcation of blood at the lesion site 24 h after injury
conﬁrmed that, whereas the lesion volumes were not signiﬁcantly different between clip-compressed and contused rats, the lesion site of
rats contained signiﬁcantly more blood after contusion SCI. A qualitative
evaluation of histological sections from rats after C5 hemi-contusion
also showed a great deal of intraspinal hemorrhage. The increased
frank bleeding into the spinal cord after contusion SCI compared to
clip-compression SCI may explain why the two injury models respond
differently to the CD11d mAb. This treatment targets the interaction between activated white blood cells and the intact vascular endothelium
to reduce neutrophil and monocyte inﬁltration of the injury site.
Within the injured spinal cord, inﬂammatory chemoattractant signals recruit leukocytes preferentially via an abundant venous system
within the gray matter. This process is further enhanced as spinal venules, unlike arterioles, constitutively express intracellular adhesion
molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1) and
platelet-endothelial cell adhesion molecule (PECAM) (Schnell et al.,
1999a) that mediate the extravasation of leukocytes into the lesion.
More recently, it has been proposed that an additional source of inﬂammatory leukocytes, particularly monocyte/macrophages, is the bloodcerebrospinal ﬂuid interface at the brain choroid plexus that delivers
leukocytes to the lesion via the central canal and CSF (Shechter et al.,
2013). A one minute clip-compression SCI leaves the cord tissue locally
bruised (size deﬁned by width of the compression clip), but also affected by ischemia-reperfusion injury. Thus, despite the local hemorrhage

Fig. 6. Gross inspection of the lesion sites in T12 clip-compressed and T12 contused spinal cords reveal different pathologies. Injured spinal cords were compared at 24 h after (A)T12 injury
by 35 g clip-compression (n = 4, top row) or (B) a 200 kdyne contusion SCI with a 30 s dwell time (n = 4, bottom row). Both resulted in signiﬁcant hemorrhage on the cord surface but the
clip-compression injury produced a hematoma that was conﬁned to a ~2 mm wide line at the site of injury that approximated the width of the aneurysm clip while the contusion injury
produced a much larger hematoma that extended 4 mm or more in the rostral and caudal directions from the centre of the injury. Scale bar = 5 mm.
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Fig. 7. Lesion assessment reveals greater amounts of intraspinal blood after T12 contusion SCI compared to T12 clip-compression SCI. (A) Representative photomicrographs of hematoxylin
and eosin stained sections after T12 contusion, T12 clip-compression, and a C5 hemi-contusion SCI, (n = 5/contusion group; n = 6/clip compression, n = 4/C5 hemi-contusion
group). Bar = 200 μm. (B) There was no signiﬁcant difference in lesion volume between the clip-compression and contusion SCI rats at 24 h post-injury but the amount of
intraspinal blood in the T12 contusion SCI rats was signiﬁcantly greater than that in the T12 clip-compression SCI rats.

in the bruised area of the cord, the surrounding vasculature, central
canal and meningeal membrane are left intact. The vasculature will,
however, become more permeable due the presence of ischemia-reperfusion induced reactive oxygen species, complement and the release of
proteases by the ever increasing number of neutrophils, all of which
loosen intracellular adhesions that normally maintain the spinal cord
blood barrier (Anwar et al., 2016; Takigawa et al., 2010). The constitutively expressed adhesion molecules on venules will immediately facilitate the early entry of the arriving neutrophils and later monocyte/
macrophages into the injured spinal cord via adhesion moleculeintegrin mediated processes in response to pro-inﬂammatory signals
(Anwar et al., 2016; Fleming et al., 2006; Saville et al., 2004). Similarly,
the migration of leukocytes from the CSF and meningeal membranes
will also require adhesion molecule-integrin interactions in response
to the same pro-inﬂammatory signals. Hence, therapies directed at
blocking leukocyte migration by preventing adhesion molecule-integrin
interactions into the lesion can have impact in preclinical models, as we
have previously demonstrated (Fleming et al., 2008; Gris et al., 2004;
Saville et al., 2004). However, in SCI models such as that generated by
the piston-driven contusion impactor, signiﬁcant intraparenchymal
hemorrhage extends both rostrally and caudally from the epicenter
(Anwar et al., 2016) and the structures that constrain CSF are mechanically disrupted. Therefore, the adhesion molecule integrin-mediated
process of leukocyte recruitment is no longer the dominant means by
which leukocytes gain access to the lesion. Blood leukocytes will enter
freely into the lesion area until thrombosis, and initial vascular repair
take over in the ﬁrst 24 to 48 h (Bartanusz et al., 2011; Fehlings et al.,
1989). Under these circumstances, early anti-adhesion moleculeintegrin strategies to block leukocyte extravasation will not be effective,
as we have demonstrated here.
Therapeutic strategies for the treatment of SCI are typically developed to interfere with speciﬁc molecular and/or cellular events. Thus,

it stands to reason that their effectiveness will rely upon the extent to
which the pathophysiology triggered by an injury depends upon the
targeted molecular or cellular event. The CD11d mAb targets leukocyte
inﬁltration of the injured spinal cord by disrupting the CD11d-VCAM-1
interaction necessary for diapedesis. We suggest that the CD11d mAb
was not effective in the contusion SCI models tested because the pathology post-contusion is dominated by the severe primary injury and accompanying increased intraspinal hemorrhage. Secondary damage
and inﬂammation, that are driven by leukocyte diapedesis and CD11dVCAM-1 interactions are less important in this model of SCI compared
to clip-compression SCI. In addition a greater primary injury after contusion SCI could have reduced the amount of tissue available as a substrate
for neuroprotection. Our results highlight the importance of characterizing the pathophysiological mechanisms at work in various models of
SCI or of the same model in different hands when interpreting the results of therapeutic studies. Negative results of preclinical therapeutic
studies are important to steer the research ﬁeld toward developing
beneﬁcial therapies but we must be mindful that inconsistent results
between models may simply result from the fact that the pathophysiological mechanism targeted by the therapeutic is less relevant in one
model than another.
This foregoing argument suggests that the usefulness of the CD11d
mAb therapy in human SCI will depend on whether the pathology in a
particular case of SCI is driven by CD11d-VCAM interactions and consequent secondary injury or by other mechanisms. Neutrophil and macrophage inﬁltration of the injured human spinal cord has been previously
described (Fleming et al., 2006). The extent to which neutrophil and
macrophage levels in the injured human spinal cord may be attributed
to hemorrhage or to CD11d-VCAM interactions is difﬁcult to assess.
Human pathological studies indicate that while hemorrhage may be a
typical feature of SCI (Miyanji et al., 2007; Tator, 1995; Witiw and
Fehlings, 2015) it is variable (Fleming et al., 2006) and may not be
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present even when predicted to be a prominent feature of the disease
(Quencer et al., 1992). The heterogeneity in the SCI patient population
suggests that each case will have its own constellation of pathophysiological mechanisms at play after injury reﬂective of the mechanism of
injury, the patient's genetics, epigenetics and pre-existing conditions.
While the clip compression model of injury may replicate many of the
pathological features of human SCI, it should be acknowledged that
most human injuries occur due to high energy trauma in which the spinal cord is “contused” with velocities that even exceed what is achieved
with typical contusion SCI models. Our results argue that a therapy's efﬁcacy in one model of SCI should prompt investigation in other SCI
models to address how it would work in different patient populations.
The extent to which secondary injury caused by inﬁltrating pro-inﬂammatory leukocytes contributes to the pathology of human SCI injury most likely will vary from patient to patient and thus the potential
therapeutic beneﬁt of the CD11d mAb to human SCI cannot be readily
determined. The fact that hemorrhage is a typical feature of acute traumatic human SCI certainly points to the importance of replicating this
pathologic feature in animal models. As shown in our paper, such hemorrhage is a prominent feature of the acute contusive mechanism of injury, and not the compressive mechanism of injury. This heterogeneity
of human SCI is important to acknowledge when considering the efﬁcacy of a particular preclinical therapy that is tested in only a single injury
paradigm. Our study uniquely demonstrates that differences in injury
mechanism in the laboratory inﬂuences therapeutic efﬁcacy. This provides a strong argument to investigate a novel treatment in more than
one preclinical injury model, which is a form of “replication” that is
somewhat distinct from, but arguably as clinically relevant as, doing a
formal replication. In this regard it is interesting to note that we (Bao
et al., 2012; Shultz et al., 2013) and others (Utagawa et al., 2008) have
demonstrated a neuroprotective effect of the CD11d mAb in models of
traumatic brain injury.
Our work indicates that the best candidates for the CD11d mAb may
be those with imaging studies suggesting limited bleeding into the injured cord or those for whom the effect of the CD11d mAb on co-morbid
conditions may justify its use. For example, the systemic inﬂammatory
response syndrome (SIRS) is a signiﬁcant contributor to morbidity and
mortality in trauma patients (Acosta et al., 1998) and frequently occurs
after SCI (Kesani et al., 2014). We have shown that the CD11d mAb
treatment reduces SIRS in spinal cord-injured rats (Bao et al., 2011;
Weaver et al., 2015). If the CD11d mAb proves efﬁcacious in the treatment of SIRS then spinal cord-injured people that meet the criteria for
SIRS (Kesani et al., 2014) may be the ideal candidates for evaluating
the effects of the anti-CD11d treatment on recovery from SCI.
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